dc.contributor.author
Sierra Ortigosa, Josep Maria
dc.contributor.author
Viñas, Miquel
dc.date.accessioned
2026-02-19T21:15:26Z
dc.date.available
2026-02-19T21:15:26Z
dc.date.issued
2026-02-17T08:36:49Z
dc.date.issued
2026-02-17T08:36:49Z
dc.date.issued
2021-02-24
dc.date.issued
2026-02-17T08:36:50Z
dc.identifier
https://hdl.handle.net/2445/226948
dc.identifier.uri
https://hdl.handle.net/2445/226948
dc.description.abstract
Antimicrobial resistance is widely recognized as one of the major challenges of public health worldwide, as infections by multidrug-resistant (MDR) bacteria have reached worrisome levels. Three levels of antibiotic resistance have been described [Citation1]: i) multi-resistance (resistance to at least three different families of antimicrobials), ii) extreme resistance (resistance to all antimicrobials except colistin) and iii) pan-drug resistance (resistance to all available antimicrobials).
dc.format
application/pdf
dc.publisher
Informa Healthcare
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1080/17460441.2021.1892072
dc.relation
Expert Opinion on Drug Discovery, 2021, vol. 16, num.6, p. 601-604
dc.relation
https://doi.org/10.1080/17460441.2021.1892072
dc.rights
(c) Informa Healthcare, 2021
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Medicaments antibacterians
dc.subject
Anàlisi de pèptids
dc.subject
Antibacterial agents
dc.subject
Analysis of peptides
dc.title
Future prospects for Antimicrobial peptide development: peptidomimetics and antimicrobial combinations
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion
